Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram
General Counsel · BlossomHill Therapeutics, Inc. · Common Stock
Open-market purchase
$35K reported value · 2.0% of prior position
Disclosed 0 business days after execution (deadline: 2)
1 prior trade recorded in this security
1 other actor traded the same direction within 14 days
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 5 | Liptak Vincent PaulGeneral Counsel | Derivative conversion | C | — 22.7K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Agrawal SundeepDirector | Grant or award | A | — 23.9K sh | Aug 10, 2026 traded Aug 6, 2026 | |
| 9 | Agrawal SundeepDirector | Derivative conversion | C | — 578.5K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Cui Jingrong JeanDirector, President and CEO, 10% Owner | Derivative conversion | C | — 124.8K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Cui Jingrong JeanDirector, President and CEO, 10% Owner | Grant or award | A | — 676.2K sh | Aug 10, 2026 traded Aug 6, 2026 | |
| 9 | Cui Jingrong JeanDirector, President and CEO, 10% Owner | Derivative conversion | C | — 1.60M sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Cui Jingrong JeanDirector, President and CEO, 10% Owner | Derivative conversion | C | — 113.4K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Cui Jingrong JeanDirector, President and CEO, 10% Owner | Derivative conversion | C | — 124.8K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Li YishanDirector, Executive Chairman, 10% Owner | Derivative conversion | C | — 124.8K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Oxnard Geoffrey RaymondChief Medical Officer | Grant or award | A | — 61.8K sh | Aug 10, 2026 traded Aug 6, 2026 | |
| 9 | Liptak Vincent PaulGeneral Counsel | Grant or award | A | — 46.6K sh | Aug 10, 2026 traded Aug 6, 2026 | |
| 5 | Liptak Vincent PaulGeneral Counsel | Derivative conversion | C | — 22.7K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Cui Jingrong JeanDirector, President and CEO, 10% Owner | Derivative conversion | C | — 1.60M sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Keyes Jason AChief Financial Officer | Grant or award | A | — 56.7K sh | Aug 10, 2026 traded Aug 6, 2026 | |
| 9 | Li YishanDirector, Executive Chairman, 10% Owner | Derivative conversion | C | — 1.60M sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 13 | Li YishanDirector, Executive Chairman, 10% Owner | Derivative conversion | C | — 113.4K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Li YishanDirector, Executive Chairman, 10% Owner | Grant or award | A | — 112.7K sh | Aug 10, 2026 traded Aug 6, 2026 | |
| 9 | Li YishanDirector, Executive Chairman, 10% Owner | Derivative conversion | C | — 1.60M sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Li YishanDirector, Executive Chairman, 10% Owner | Derivative conversion | C | — 113.4K sh | Aug 10, 2026 traded Aug 10, 2026 | |
| 9 | Li YishanDirector, Executive Chairman, 10% Owner | Derivative conversion | C | — 124.8K sh | Aug 10, 2026 traded Aug 10, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $35,200
Liptak Vincent Paul filed this Form 4 reporting a open-market purchase of BLSM on Aug 10, 2026. It became public on Aug 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.